Les neuroblastomes de l'enfant. A propos de 23 cas.

Abdominal Neoplasms/diagnosis/genetics/therapy; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Male; Neuroblastoma/diagnosis/genetics/therapy; Retrospective Studies; Thoracic Neoplasms/diagnosis/genetics/therapy

Abstract :

[en] In this retrospective study, we analyse epidemiology, clinical symptoms and therapeutic results in a group of 23 children with neuroblastoma. Half of them were less than 2 years of age; in 19 of 23, the primitive tumour was abdominal; 35% of them were initially metastatic. The overall survival was 83% at 5 years and the event free survival, 75% at 5 years. Pronostic factors are age, extension of the disease at diagnosis, biologic parameters and genetic study of the neuroblast cells (amplification of N-myc oncogen). Our study shows the deleterious effect of bone lesions.

Disciplines :

Hematology

Author, co-author :

Piette, Catherine ; Centre Hospitalier Universitaire de Liège - CHU > Psychiatrie et psychologie médicale

Dresse, Marie-Françoise ; Centre Hospitalier Universitaire de Liège - CHU > Pédiatrie CHR

Forget, Patricia ; Centre Hospitalier Universitaire de Liège - CHU > Pédiatrie CHR

Schmitz, Véronique

Demarche, Martine

Erpicum, Patrice

Closon, Marie-Thérèse ; Centre Hospitalier Universitaire de Liège - CHU > Radiothérapie

Rutten, Isabelle

Paulus, Patrick

Vivegnis, Danielle

More authors (3 more)

Language :

French

Title :

Les neuroblastomes de l'enfant. A propos de 23 cas.

Alternative titles :

[en] Clinical evaluation of 23 children with neuroblastoma. The experience of a single institution

Publication date :

2005

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

173-80

Peer reviewed :

Peer reviewed

Available on ORBi :

since 23 March 2009

Statistics

Number of views

374 (7 by ULiège)

Number of downloads

1734 (5 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Gurney JG, Davis S, Severson RK, et al.-Trends in cancer incidence among children in the U.S. Cancer, 1996, 78, 532-541.
Katzenstein H, Bowman LC, Brodeur GM, et al.-Prognostic significance of age, MUCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience-a Pediatric Oncology Group study. J Clin Oncol, 1998, 16, 2007-2017.
Shimada H, Ambros IM, Dehner LP, et al.-The International Neuroblastoma Pathology Classification (the Shimada system). Cancer, 1999, 86, 364-372.
Plantaz D, Rubie H, Michon J, et al.-The treatment of neuroblastoma with intraspinal extension with chemotherapy followed by surgical removal of residual disease. A prospective study of 42 patients - results of the NBL 90 Study of the French Society of Pediatric Oncology. Cancer, 1996, 78, 311-319.
Manstragelo R, Tornesello A, Mastrangelo S.-Role of 131I- mataiodobenzylguanidine in the treatment of neuroblastoma. Med Pediatr Oncol, 1998, 31, 22-26.
Chompret A, de Vathaire F, Brugieres L, et al.-Excess of cancer in relatives of patients with neuroblastoma. Med Pediatr Oncol, 1998, 31, 211A.
Brodeur GM, Ambros PF.-Genetic and biological markers of prognosis in neuroblastoma, in Brodeur GM, Sawada T, Tsuchida Y, Voute PA, Ed., Neuroblastoma. Elsevier Science, Amsterdam, 2000, 355-369.
Villablanca JG, Khan AA, Avramis VI, et al.-Phase I trial of 13-cisretinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Onco, 1995, 13, 894-901.
Koh PS, Raffensperger JG, Berry S, et al.-Long-term outcome in children with opsoclonus-myoclonus and ataxia and coincident neuroblastoma. J Pediatr, 1994, 125, 712-716.
Connolly AM, Pestronck A, Mehta S, et al.-Serum autoantibodies in childhood opsoclonus-myoclonus syndrome: an analysis of antigenic targets in neural tissues (see comments). J Pediatr, 1997, 130, 878-884.
Brodeur GM, Maris JM, Yamashiro DJ, et al.-Biology and genetics of human neuroblastomas. J Pediatr Hematol Oncol, 1997, 19, 93-101.
Matthay KK, Perez C, Seeger RC, et al.-Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J Clin Oncol, 1998, 16, 1256-1264.
Matthay KK, Villablanca JG, Seeger RC, et al.-Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med, 1999, 34, 1165-1173.
Hartmann O, Berthold F.-Treatment of advanced neuroblastoma: the European experience, in Brodeur GM, Sawada T, Tsuchida Y, Voute PA, Ed., Neuroblastoma Elsevier Science, Amsterdam, 2000, 437-452.
Matthay KK, Castleberry RP.-Treatment of advanced neuroblastoma: the US experience, in Brodeur GM, Sawada T, Tsuchida Y, Voute PA, Ed., Neuroblastoma Elsevier Science, Amsterdam, 2000, 417-436.
Berthold F, Trechow R, Utsch S, et al.-Prognostic factors in metastatic neuroblastoma. A multivariate analysis of 182 cases. Am J Pediatr Hematol Oncol, 1992, 14, 207-215.
Rubie H, Delattre O, Hartmann O, et al.-Loss of chromosome 1p may have a prognostic value in localised neuroblastoma: results of the French NBL 90 Study; Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP). Eur J Cancer, 1997, 33, 1917-1922.
Rubie H, Hartmann O, Michon J, et al.-N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 Study. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique. J Clin Oncol, 1997, 15, 1171-1182.
Bordow SB, Norris MD, Haber PS, et al.-Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. J Clin Oncol, 1998, 16, 3286-3294.
De Bernardi B, Pianca C, Boni L, et al.-Disseminated neuroblastoma (stage IV and IV-S) in the first year of life. Outcome related to age and stage. Italian Cooperative Group on Neuroblastoma. Cancer, 1992, 70, 1625-1633.
DuBois SG, Kalilka Y, Lukens JN, et al.-Metastatic sites in stage IV and IVs neuroblastoma correlate with age, tumour biology, and survival. J Pediatr Hematol Oncol, 1999, 21, 181-189.
Halperin EC, Constine LS, Tarbell NJ, et al.-Pediatric radiation oncology. Third edition. Raven Press, New York, 1999, 92-94.
Manstragelo R, Tornesello A, Mastrangelo S.-Role of 131I- metaiodobenzylguanidine, in Brodeur GM, Maris JM., Neuroblastoma. In: Pizzo PA, Poplack DG. - Principles and Practice of Pediatric Oncology. Lippincott Williams & Wilkins, USA, 4th ed. 2002, 31, 895-937.
Hishiki T, Nimura Y, Isogai E, et al.-Glial cell line-derived neurotrophic factor/neurturin-induced differentiation and its enhancement by retinoic acid in primary human neuroblastomas expressing c-Ret GFR alpha-1, and GFR alpha-2. Cancer Res, 1998, 58, 2158-2165.
Yu AL, Uttenreuther-Fischer MM, Huang CS, et al.-Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch 14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol, 1998, 16, 2169-2180.
Yu AL, Batova A, Alvarada C, et al.-Usefulness of a chimeric anti GD2 (ch14.18) and GM-CSF for refractory neuroblastoma: a POG Phase II study. Proc. Am soc Clin Oncol, 1997, 16, 513a.
Brodeur GM, Maris JM.-Neuroblastoma., in Pizzo PA, Poplack DG Ed., Principles and Practice of Pediatric Oncology. Lippincott Williams & Wilkins, 4th ed., USA, 2002, 31, 895-937.
Berthold F, Trechow R, Utsch S, et al.-Prognostic factors in metastatic neuroblastoma. A multivariate analysis of 182 cases. Am J Pediatr Hematol Oncol, 1992, 14, 207-215.
Michon J (Study Coordinator, Curie).-LNESG2 phase III study and trial protocol: surgery with or without adjuvant chemotherapy for resected INSS stage 1,2 and 3 neurobalstoma PTS according to biological risk factors. November 2001
Labenstein R (Study Coordinator, Vienna).-E-SIOP Neuroblastoma Protocol: Treatment of children over the age of 1 year with unresectable localised neuroblatoma without MYCN amplification. April 2000